Pfizer
PFE
$30.52
+1.90%
Pfizer is one of the world's largest pharmaceutical companies, discovering, developing, and commercializing prescription medicines and vaccines across oncology, immunology, cardiology, internal medicine, and anti-infectives, with its Biopharma segment generating the overwhelming majority of revenue (roughly $14.7 billion of the $15.0 billion reported in the latest quarter). The company is a scale incumbent rather than a disruptor — its competitive identity rests on blockbuster franchises such as Prevnar, Vyndamax, and Eliquis, a deep late-stage pipeline, and a global commercial footprint spanning roughly 75,000 employees and about 40% international sales. The current investor narrative centers on the post-COVID reset: Pfizer is working to replace pandemic-era revenue with acquired and internally developed growth drivers while digesting a heavy acquisition-related debt load, and the debate hinges on whether cost discipline and pipeline execution can restore durable earnings growth after a string of volatile, impairment-driven quarters. Recent quarterly results have been choppy — a large Q4 2025 loss followed by a strong Q1 2026 and a Q2 2026 loss driven by non-operating items — which keeps sentiment focused on underlying operating momentum versus headline GAAP noise, while the stock's strong relative performance suggests the market is increasingly willing to look through the accounting volatility.…
PFE
Pfizer
$30.52
Related headlines
Investment Opinion: Should I buy PFE Today?
Rating: Hold with a constructive bias. The core thesis is that PFE's 10.4x forward PE and $10.99 billion TTM free cash flow offer value, but the stock at $30.03 already sits above the $29.26 average analyst target and near its $30.44 52-week high, so the risk/reward is balanced rather than compelling. The 26-analyst consensus is a buy (mean 2.5), yet the average target implies roughly -2.5% downside, meaning the market has largely caught up to the recovery story.
The supporting evidence is mixed but leans positive: forward PE of 10.4x versus trailing 18.3x implies expected EPS recovery to $2.45; gross margin of 74.3% and operating margin of 27.8% show pricing power; TTM free cash flow of $10.99 billion comfortably funds the 6.9% dividend; and relative strength of +19.5 points versus SPY over three months confirms momentum. However, revenue growth of only 2.6% year over year and a 125.7% payout ratio temper the quality of the earnings recovery, and debt-to-equity of 0.78 with $667 million quarterly interest expense limits flexibility.
The biggest risks that could invalidate the thesis are a repeat of large non-operating charges (Q2 2026 had a $5.36 billion other-expense line), a dividend cut if free cash flow slips, and pipeline or competitive disappointments in oncology and immunology. This Hold would upgrade to Buy if the stock pulls back toward the $25-$26 analyst low-target zone (roughly 15% downside) or if forward EPS estimates rise above $2.55, and it would downgrade to Sell if revenue growth turns negative or the payout ratio stays above 100% for another year. On valuation, PFE looks fairly valued to slightly undervalued on forward earnings but fully valued on trailing metrics and relative to the analyst average target.
Sign up to view all
PFE 12-Month Price Forecast
PFE presents a fairly balanced risk/reward at $30.03: the 10.4x forward PE and $10.99 billion free cash flow are attractive, but the stock has already rallied 22.4% in three months and trades above the average analyst target of $29.26. The 6.9% dividend yield is the anchor, yet a 125.7% payout ratio and recurring GAAP losses mean the income is not risk-free. I would upgrade to bullish if forward EPS estimates move above $2.55 or the stock pulls back toward $26-$27, and I would downgrade to bearish if revenue growth turns negative or another multi-billion-dollar charge hits reported earnings. With beta of 0.276, PFE is a defensive holding rather than a high-upside growth story, and the base case of $28-$31 captures most of the plausible 12-month outcomes.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Pfizer's 12-month outlook, with a consensus price target around $29.26 and implied upside of -4.1% versus the current price.
Average Target
$29.26
0 analysts
Implied Upside
-4.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$25 - $36
Analyst target range
Bulls vs Bears: PFE Investment Factors
The bull case rests on a forward PE of 10.4x, $10.99 billion in TTM free cash flow, a 6.9% dividend yield, and strong relative strength (+19.5 points versus SPY over three months), while the bear case centers on GAAP losses, a 125.7% payout ratio, 0.78 debt-to-equity, and only 2.6% revenue growth. On balance, the evidence currently favors the bulls because cash generation and the forward earnings multiple provide a margin of safety, and the market has rewarded the stock with a 22.4% three-month gain. The single most important tension is whether the $2.45 consensus EPS for the forward year materializes; if it does, the 10.4x forward PE is deeply undervalued, but if impairments or non-operating charges persist, the trailing 18.3x PE and 125.7% payout ratio look stretched. The stock sitting just above the average analyst target of $29.26 means the easy money has likely been made, and further gains require fundamental confirmation.
Bullish
- Deep value on forward earnings: PFE trades at a forward PE of 10.4x against trailing PE of 18.3x, implying the market expects EPS to roughly double to the $2.45 consensus estimate from the current $0.055 trailing figure. A 10.4x forward multiple is a steep discount to the broad healthcare sector and prices in substantial skepticism, leaving room for re-rating if earnings normalize.
- Strong relative strength and momentum: PFE has gained 22.4% over three months versus a 2.85% gain for the S&P 500, a relative strength of +19.5 percentage points, and is up 21.7% over one year versus SPY's 13.1%. The stock is near its 52-week high of $30.44 (current $30.03), signaling the market is rewarding the post-COVID reset narrative.
- Robust free cash flow and margins: TTM free cash flow is $10.99 billion and the latest quarter delivered a 72.8% gross margin and 31.3% operating margin despite a GAAP net loss. Operating income of $4.71 billion in Q2 2026 shows the core business remains highly cash-generative, funding the 6.9% dividend yield.
- Analyst consensus buy with upside: 26 analysts rate PFE a buy (mean recommendation 2.5) with an average target of $29.26 and a high target of $36.00. The high target implies roughly 20% upside from $30.03, and consensus EPS of $2.45 versus the depressed trailing $0.055 suggests earnings recovery is the base case.
Bearish
- GAAP losses and earnings volatility: PFE reported a Q2 2026 net loss of $246 million (EPS -$0.043) and a Q4 2025 loss of $1.65 billion (EPS -$0.29), driven by non-operating items such as a $5.36 billion other-expense line in Q2 2026. This earnings volatility makes trailing metrics unreliable and raises questions about the quality and sustainability of reported profits.
- Heavy debt and interest burden: Debt-to-equity stands at 0.78 and quarterly interest expense is $667 million, consuming a meaningful share of operating income. The acquisition-driven balance sheet leaves limited flexibility and makes PFE sensitive to refinancing costs and credit conditions.
- Dividend payout exceeds earnings: The payout ratio is 125.7%, meaning the 6.9% dividend yield is not covered by trailing GAAP earnings. While free cash flow of $10.99 billion supports the payment, a payout above 100% of earnings is a red flag if cash flow deteriorates or impairments recur.
- Sluggish revenue growth: Q2 2026 revenue grew only 2.6% year over year to $15.03 billion, a modest pace for a company that needs to replace pandemic-era revenue. Consensus revenue of $53.3 billion for the year implies limited top-line acceleration, leaving the thesis dependent on cost cuts and pipeline execution.
PFE Technical Analysis
Beta
0.28
0.28x market volatility
Max Drawdown
-17.1%
Largest decline past year
52-Week Range
$24-$31
Price range past year
Annual Return
+25.6%
Cumulative gain past year
| Period | PFE Return | S&P 500 |
|---|---|---|
| 1m | +7.0% | -0.9% |
| 3m | +22.0% | +1.2% |
| 6m | +15.9% | +4.9% |
| 1y | +25.6% | +11.2% |
| ytd | +21.2% | +10.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PFE Fundamental Analysis
Quarterly Revenue
$15.0B
2026-06
Revenue YoY Growth
+2.6%
YoY Comparison
Gross Margin
72.8%
Latest Quarter
Free Cash Flow
$11.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PFE Overvalued?
PE
18.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 7x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are elevated by PFE's earnings volatility and balance-sheet leverage. The company posted a Q2 2026 net loss of $246 million and a Q4 2025 loss of $1.65 billion, with a $5.36 billion other-expense line in Q2 2026 driving the latest shortfall, showing that non-operating items can overwhelm a 31.3% operating margin. Debt-to-equity of 0.78 and quarterly interest expense of $667 million absorb cash flow, while the 125.7% payout ratio means the 6.9% dividend is not covered by GAAP earnings and depends on the $10.99 billion TTM free cash flow holding up. Revenue growth of just 2.6% year over year in Q2 2026 leaves little cushion if a key franchise such as Prevnar, Vyndamax, or Eliquis faces pricing pressure or generic competition.
Market and competitive risks include valuation compression and sector rotation. PFE's forward PE of 10.4x is low, but the trailing PE of 18.3x and price-to-sales of 2.26x are not distressed, and the stock's 22.4% three-month rally has pushed it to $30.03, near the 52-week high of $30.44 and above the average analyst target of $29.26. Beta of 0.276 limits market-correlation risk, but the low beta also means PFE may lag in strong risk-on rallies, and healthcare sector rotation away from large-cap pharma would hit the stock. Competitive threats are real: recent news highlights rivals advancing in oncology and immunology (Roche's Tecentriq label expansion, Novartis's Rhapsido approval, Moderna's cancer vaccine progress), and J&J's raised guidance and path to $100 billion in revenue underscores how aggressively peers are competing for the same growth pools.
A worst-case scenario would combine a failure of the $2.45 consensus EPS to materialize, another multi-billion-dollar impairment, and a dividend cut or freeze. In that chain, the stock could retest its 52-week low of $23.62, which is roughly 21% below the current $30.03, and the analyst low target of $25.00 implies about 17% downside. The historical max drawdown of -17.09% is a useful guide: a repeat of that magnitude from $30.03 would put the stock near $24.90, consistent with the low-target zone. An investor could realistically lose 17% to 21% from current levels in this adverse scenario, and the 6.9% yield would only partially offset that loss.
FAQ
The most severe risk is earnings volatility from non-operating charges: Q2 2026 included a $5.36 billion other-expense line that turned a $4.71 billion operating profit into a $246 million net loss. Second is dividend sustainability, with a 125.7% payout ratio meaning the 6.9% yield depends on $10.99 billion in TTM free cash flow holding up. Third is balance-sheet leverage, with debt-to-equity of 0.78 and $667 million in quarterly interest expense limiting flexibility. Fourth is competitive and pipeline risk, as peers such as Roche, Novartis, and J&J advance in oncology and immunology while PFE grows revenue only 2.6% year over year. A worst case could see the stock fall 17-21% toward the $23.62-$25.00 range.
The 12-month forecast has three scenarios: a 50% probability base case of $28-$31 around the $29.26 analyst average target, a 25% probability bull case of $33-$36 anchored by the $36 high target, and a 25% probability bear case of $23.62-$25.00 anchored by the 52-week low and $25 low target. The base case is most likely because it assumes revenue growth stays near 2.6%, operating margins hold around 27.8%, and free cash flow near $11 billion covers the dividend. The key assumption is that the $2.45 consensus EPS is delivered without another multi-billion-dollar impairment. A break above $31 would signal the bull case is taking hold, while a drop below $28 would point toward the bear scenario.
PFE looks undervalued on forward earnings but fairly valued on trailing and relative metrics. The forward PE of 10.4x is well below the trailing PE of 18.3x, implying the market expects EPS to recover to the $2.45 consensus from the current $0.055. Price-to-sales of 2.26x and EV/EBITDA of 12.4x are moderate for a large-cap pharma with 74.3% gross margins. However, the stock at $30.03 is slightly above the $29.26 average analyst target and near the $30.44 52-week high, suggesting the recovery is largely priced in. The market appears to expect modest revenue growth of about 2.6% and stable cash flow rather than a dramatic turnaround.
PFE is a reasonable buy for income-focused investors but only a Hold for growth-oriented ones at the current $30.03 price. The stock offers a 6.9% dividend yield, a 10.4x forward PE, and $10.99 billion in TTM free cash flow, which provides a margin of safety. However, it trades above the $29.26 average analyst target and near the $30.44 52-week high after a 22.4% three-month rally, so near-term upside is limited. The biggest downside risk is a repeat of large non-operating charges, such as the $5.36 billion other-expense line in Q2 2026, which could push the stock toward the $25 analyst low target. It is a good buy for patient investors seeking yield and low beta (0.276), ideally on a pullback toward $26-$27.
PFE is better suited for long-term income-oriented holding than short-term trading. Its beta of 0.276 means low volatility, so short-term price moves are modest, and the 6.9% dividend yield rewards patience. The earnings picture is choppy, with GAAP losses in Q2 2026 and Q4 2025, so a long horizon of at least 2-3 years allows the post-COVID reset and pipeline execution to play out. Short-term traders face limited upside given the stock is above the $29.26 average target and near the $30.44 52-week high. A suggested minimum holding period is two to three years to capture dividend income and potential re-rating toward the $33-$36 bull-case range.